Posted on 13 May 2014
Stem cells are cells found in all multicellular organisms, that can divide and differentiate into diverse specialized…
Posted on 04 October 2012
In bio news is Rainbow Coral Corp.’s (OTCBB: RBCC) biotech subsidiary, Rainbow Biosciences, which is on a hunt to find potential partners for research collaboration on stem cells in China
Posted on 19 October 2011
Proteonomix has that it has decided to examine the possibility of licensing its stem cell diabetes related technology to another company in light of continued progress toward its trial of UMK-121, its stem cell treatment for patients awaiting liver transplant to overcome End Stage Liver Disease (“ESLD”).
Posted on 12 May 2011
The UK’s Shire has been making a series of small-$3 million to $5 million-investments in stem cell developers
Posted on 10 December 2010
Cephalon, the largest biotechnology company in the regenerative medicine sector, have licensed Mesenchymal Precursor Stem Cell (MPC) therapeutics from Mesoblast for over $2 billion.
Posted on 31 January 2013
Biotech IPO: Stemline Therapeutics, an emerging biotech company, successfully completed its biotech IPO yesterday with shares rising 18% on opening
Posted on 23 February 2012
Report from Financial Chronicle. Stem cell bank Stemade, which is into storing stem cells extracted from the tooth, is looking at foraying into the overseas markets like Singapore, West Asia and Australia in the coming two years. The company also wants to raise around $8 million to $10 million from Private equity funds to drive more »
Posted on 14 February 2012
The news in the past week has been the lack of deal news. The past week has been very quiet on the dealmaking front, with very little of significance in terms of deals from bigpharma or deals with a high headline value
Posted on 24 January 2012
From Boston Business Journal. Verastem, a one-year old startup focused on developing drugs that target cancer stem cells, plans to set pricing for its IPO during the week of Jan. 23, the IPO research firm Renaissance Capital reported, Friday.
Posted on 22 October 2014
The field of regenerative medicine is an up and coming new approach of targeting and treating diseases, it involves the repair and restoration of previously damaged tissues or organs in the body. The regenerative medicine market was worth $16bn in 2013 and industry analysts predict that this will leap to over $60bn by 2020. The more »